Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors-Reference-Cited by-同舟云学术

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors

Published:2017-04-19 Issue:6 Volume:79 Page:1257-1265
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Aspeslagh Sandrine^ORCID,Shailubhai Kunwar,Bahleda Rastilav,Gazzah Anas,Varga Andréa,Hollebecque Antoine,Massard Christophe,Spreafico Anna,Reni Michele,Soria Jean-Charles

Funder

nerviano

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3303-z/fulltext.html

Reference25 articles.

1. O’Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 13:417–430. doi: 10.1038/nrclinonc.2016.26

2. Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17:93–115. doi: 10.1038/nrc.2016.138

3. Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169:107–114. doi: 10.1016/S0304-3835(01)00530-4

4. Amatu A, Sartore-Bianchi A, Siena S (2016) NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:1–10. doi: 10.1136/esmoopen-2015-000023

5. Ardini E, Menichincheri M, Banfi P et al (2016) Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 15:628–639. doi: 10.1158/1535-7163.MCT-15-0758

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Synthesis of New bis-oxindole and Spiro(triazole-oxindole) as CDK4 Inhibitors with Potent Anti-breast Cancer Activity;Medicinal Chemistry;2024-01

2. Structural Insights into N-heterocyclic Moieties as an Anticancer Agent against Hepatocellular Carcinoma: An Exhaustive Perspective;Mini-Reviews in Medicinal Chemistry;2023-10

3. Senescence program and its reprogramming in pancreatic premalignancy;Cell Death & Disease;2023-08-17

4. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer;International Journal of Molecular Sciences;2023-08-03

5. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16